Literature DB >> 16872288

Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance.

J D Steckbeck1, H J Grieser, T Sturgeon, R Taber, A Chow, J Bruno, M Murphy-Corb, R C Montelaro, K S Cole.   

Abstract

BACKGROUND: Increasing evidence suggests that an effective AIDS vaccine will need to elicit broadly neutralizing antibody responses. However, the mechanisms of antibody-mediated neutralization have not been defined. Previous studies from our lab have identified significant differences in the rates of antibody binding to trimeric SIV envelope proteins that correlate with neutralization sensitivity. Importantly, these results demonstrate differences in monoclonal antibody (MAb) binding to neutralization-sensitive and neutralization-resistant envelope proteins, suggesting that one mechanism for virus neutralization may be related to the stability of antibody binding. To date, little has been done to evaluate the binding properties of polyclonal serum antibodies elicited by SIV infection or vaccination.
METHODS: In the current study, we translate these findings with MAbs to study antibody binding properties of polyclonal serum antibody responses generated in rhesus macaques infected with attenuated SIV. Quantitative and qualitative binding properties of well-characterized longitudinal serum samples to trimeric, recombinant SIV gp140 envelope proteins were analyzed using surface plasmon resonance (SPR) technology (Biacore).
RESULTS: Results from these studies identified two antibody populations in most of the samples analyzed; one antibody population exhibited fast association/dissociation rates (unstable) while the other population demonstrated slower association/dissociation rates (stable). Over time, the percentage of the total binding response of each antibody population evolved, demonstrating a dynamic evolution of the antibody response that was consistent with the maturation of antibody responses defined using our standard panel of serological assays. However, the current studies provided a higher resolution analysis of polyclonal antibody binding properties, particularly with respect to the early time-points post-infection (PI), that is not possible with standard serological assays. More importantly, the increased stability of the antibody population with time PI corresponded with potent neutralization of homologous SIV in vitro.
CONCLUSIONS: These results suggest that the stability of the antibody-envelope interaction may be an important mechanism of serum antibody virus neutralization. In addition, measurements of the 'apparent' rates of association and dissociation may offer unique numerical descriptors to characterize the level of antibody maturation achieved by candidate vaccine strategies capable of eliciting broadly neutralizing antibody responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872288      PMCID: PMC3361734          DOI: 10.1111/j.1600-0684.2006.00173.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  47 in total

1.  The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.

Authors:  R J Center; P L Earl; J Lebowitz; P Schuck; B Moss
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial.

Authors:  C Scheibenbogen; P Romero; L Rivoltini; W Herr; A Schmittel; J C Cerottini; T Woelfel; A M Eggermont; U Keilholz
Journal:  J Immunol Methods       Date:  2000-10-20       Impact factor: 2.303

Review 3.  Developments in preclinical AIDS vaccine efficacy models.

Authors:  W M Bogers; C Cheng-Mayer; R C Montelaro
Journal:  AIDS       Date:  2000       Impact factor: 4.177

4.  Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry.

Authors:  W J Moretto; L A Drohan; D F Nixon
Journal:  AIDS       Date:  2000-11-10       Impact factor: 4.177

5.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

6.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

7.  Direct measurement of CD8+ T cell responses in macaques infected with simian immunodeficiency virus.

Authors:  S M Donahoe; W J Moretto; R V Samuel; K J Metzner; P A Marx; T Hanke; R I Connor; D F Nixon
Journal:  Virology       Date:  2000-07-05       Impact factor: 3.616

8.  CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Authors:  T M Allen; B R Mothé; J Sidney; P Jing; J L Dzuris; M E Liebl; T U Vogel; D H O'Connor; X Wang; M C Wussow; J A Thomson; J D Altman; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

9.  Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.

Authors:  K M Lockridge; M Chien; G A Dean; K Stefano Cole; R C Montelaro; P A Luciw; E E Sparger
Journal:  Virology       Date:  2000-07-20       Impact factor: 3.616

10.  Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virus.

Authors:  T M Fu; D C Freed; W L Trigona; L Guan; L Zhu; R Long; N V Persaud; K Manson; S Dubey; J W Shiver
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

View more
  9 in total

1.  Probing the functional heterogeneity of surface binding sites by analysis of experimental binding traces and the effect of mass transport limitation.

Authors:  Juraj Svitel; Hacène Boukari; Donald Van Ryk; Richard C Willson; Peter Schuck
Journal:  Biophys J       Date:  2006-12-08       Impact factor: 4.033

2.  Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.

Authors:  Brendan M Giles; Stephanie J Bissel; Jodi K Craigo; Dilhari R Dealmeida; Clayton A Wiley; Terrence M Tumpey; Ted M Ross
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

Review 3.  Dissecting the humoral immune response to simian immunodeficiency virus: mechanisms of antibody-mediated virus neutralization.

Authors:  Jonathan D Steckbeck; Kelly Stefano Cole
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.

Authors:  Delphine C Malherbe; Nicole A Doria-Rose; Lynda Misher; Travis Beckett; Wendy Blay Puryear; Jason T Schuman; Zane Kraft; Jean O'Malley; Motomi Mori; Indresh Srivastava; Susan Barnett; Leonidas Stamatatos; Nancy L Haigwood
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

Review 5.  Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.

Authors:  Joanna L Richens; Richard A Urbanowicz; Elizabeth A M Lunt; Rebecca Metcalf; Jonathan Corne; Lucy Fairclough; Paul O'Shea
Journal:  Respir Res       Date:  2009-04-22

Review 6.  Specific pathogen free macaque colonies: a review of principles and recent advances for viral testing and colony management.

Authors:  JoAnn L Yee; Thomas H Vanderford; Elizabeth S Didier; Stanton Gray; Anne Lewis; Jeffrey Roberts; Kerry Taylor; Rudolf P Bohm
Journal:  J Med Primatol       Date:  2016-03-01       Impact factor: 0.667

7.  Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus.

Authors:  Donald M Carter; Chalise E Bloom; Eduardo J M Nascimento; Ernesto T A Marques; Jodi K Craigo; Joshua L Cherry; David J Lipman; Ted M Ross
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

8.  Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes.

Authors:  Jonathan D Steckbeck; Chengqun Sun; Timothy J Sturgeon; Ronald C Montelaro
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

9.  Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Authors:  Rick A Bright; Donald M Carter; Corey J Crevar; Franklin R Toapanta; Jonathan D Steckbeck; Kelly S Cole; Niranjan M Kumar; Peter Pushko; Gale Smith; Terrence M Tumpey; Ted M Ross
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.